This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) Cologuard Growth Robust Amid Margin Woes
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business is growing on impressive Cologuard volume growth and revenue contributions from the PreventionGenetics acquisition.
Cardinal Health (CAH) Ties Up to Deliver Products Via Drones
by Zacks Equity Research
Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Omnicell (OMCL) Up 10% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Omnicell's (OMCL) strategic partnerships and continued innovations for the Autonomous Pharmacy.
Illumina's (ILMN) GRAIL to Offer Galleri Test in Indianapolis
by Zacks Equity Research
Illumina's (ILMN) division GRAIL will offer the Galleri MCED blood test to eligible patients across the Community Health Network's care sites.
ENOV vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ENOV vs. OMCL: Which Stock Is the Better Value Option?
Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLYG
3 Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Amedisys' (AMED) New Tie Up to Boost At-Home Patient Care
by Zacks Equity Research
Amedisys (AMED) strengthens its Home Health and Hospice business reach by partnering with Memorial Hermann.
Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.
McKesson's (MCK) Latest JV to Boost Cancer Treatment Options
by Zacks Equity Research
McKesson's (MCK) latest activities in the oncology care space is expected to serve a wider patient pool.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Zacks Industry Outlook Highlights Omnicell, Axonics and Outset Medical
by Zacks Equity Research
Omnicell, Axonics and Outset Medical have been highlighted in this Industry Outlook article.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
3 Medical Info System Stocks Braving Industry Headwinds
by Urmimala Biswas
Medical Info Systems stocks like Omnicell, Inc. (OMCL), Axonics, Inc. (AXNX) and Outset Medical, Inc. (OM) are expected to gain despite pandemic-led disruptions.
Should Vanguard S&P SmallCap 600 Growth ETF (VIOG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOG
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Should SPDR Portfolio S&P 600 Small Cap ETF (SPSM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPSM
Here's Why You Should Hold on to DaVita (DVA) Stock For Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to strength in its DaVita Kidney Care and impressive overseas growth.
Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why You Should Hold on to Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Anthem (ANTM) Unveils Two Brands to Boost Whole Person Health
by Zacks Equity Research
Anthem (ANTM) launches Carelon and Wellpoint brands to streamline its products and services portfolio as well as bring about enhanced health plans for clients and consumers.